Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noemí Reguart

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
JTO Clinical and Research Reports|September 30, 2021
BRCA1 Expression and Outcome in Patients With <i>EGFR</i>-Mutant NSCLC Treated With Gefitinib Alone or in Combination With OlaparibNiki Karachaliou, Oscar Arrieta, Ana Giménez-Capitán, et al.
Cell Death & Disease|March 21, 2025
Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancerFernando Martín, Clara Alcon, Elba Marín, et al.
Molecular Cancer Research : MCR|October 5, 2014
Matrix stiffening and β1 integrin drive subtype-specific fibroblast accumulation in lung cancerMarta Puig, Roberto Lugo, Marta Gabasa, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinibTeresa Moran, Ramón Palmero, Mariano Provencio, et al.
Journal of Thoracic Disease|April 12, 2021
Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practiceJosé Manuel González de Aledo-Castillo, Ainara Arcocha, Iván Victoria, et al.
British Journal of Cancer|December 26, 2022
3D collagen migration patterns reveal a SMAD3-dependent and TGF-β1-independent mechanism of recruitment for tumour-associated fibroblasts in lung adenocarcinomaYago Juste-Lanas, Natalia Díaz-Valdivia, Alejandro Llorente, et al.
Oncotarget|July 8, 2016
Heterotypic paracrine signaling drives fibroblast senescence and tumor progression of large cell carcinoma of the lungRoberto Lugo, Marta Gabasa, Francesca Andriani, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2025
Prevalence and characteristics of lung cancer in families harboring Pathogenic Germline Variants in cancer predisposing genes: A 20-year retrospective analysisJuan Carlos Laguna, Lorena Moreno, Miriam Potrony, et al.
Oncotarget|January 20, 2016
ROS1 copy number alterations are frequent in non-small cell lung cancerSergi Clavé, Javier Gimeno, Ana M Muñoz-Mármol, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 11, 2023
Assessment of the change of antiemetic prophylaxis from double to triple combination in patients with high dose carboplatin chemotherapyMarta Albanell-Fernández, Ángela Pérez Sánchez, Inés Monge-Escartín, et al.
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
JTO Clinical and Research Reports|September 30, 2021
BRCA1 Expression and Outcome in Patients With <i>EGFR</i>-Mutant NSCLC Treated With Gefitinib Alone or in Combination With OlaparibNiki Karachaliou, Oscar Arrieta, Ana Giménez-Capitán, et al.
Cell Death & Disease|March 21, 2025
Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancerFernando Martín, Clara Alcon, Elba Marín, et al.
Molecular Cancer Research : MCR|October 5, 2014
Matrix stiffening and β1 integrin drive subtype-specific fibroblast accumulation in lung cancerMarta Puig, Roberto Lugo, Marta Gabasa, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinibTeresa Moran, Ramón Palmero, Mariano Provencio, et al.
Journal of Thoracic Disease|April 12, 2021
Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practiceJosé Manuel González de Aledo-Castillo, Ainara Arcocha, Iván Victoria, et al.
British Journal of Cancer|December 26, 2022
3D collagen migration patterns reveal a SMAD3-dependent and TGF-β1-independent mechanism of recruitment for tumour-associated fibroblasts in lung adenocarcinomaYago Juste-Lanas, Natalia Díaz-Valdivia, Alejandro Llorente, et al.
Oncotarget|July 8, 2016
Heterotypic paracrine signaling drives fibroblast senescence and tumor progression of large cell carcinoma of the lungRoberto Lugo, Marta Gabasa, Francesca Andriani, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2025
Prevalence and characteristics of lung cancer in families harboring Pathogenic Germline Variants in cancer predisposing genes: A 20-year retrospective analysisJuan Carlos Laguna, Lorena Moreno, Miriam Potrony, et al.
Oncotarget|January 20, 2016
ROS1 copy number alterations are frequent in non-small cell lung cancerSergi Clavé, Javier Gimeno, Ana M Muñoz-Mármol, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 11, 2023
Assessment of the change of antiemetic prophylaxis from double to triple combination in patients with high dose carboplatin chemotherapyMarta Albanell-Fernández, Ángela Pérez Sánchez, Inés Monge-Escartín, et al.
Pageof 8